STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Not yet recruiting
- Idiopathic Subglottic Tracheal Stenosis
- Everolimus Oral Tablet
- (no location specified)
2022-03-31
Mar 31, 2022G
Not yet recruiting
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Giredestrant
- +4 more
- (no location specified)
2022-03-23
Mar 23, 2022G
Completed
- Breast Cancer
- Hormone Receptor Positive Tumor
- 3 weeks Dose Induction of Everolimus
- +3 more
- Neu Isenburg, Hessen, Germany
- +13 more
2022-02-22
Feb 22, 2022M
Completed
- Bladder Cancer
- Metastatic Transitional Cell Carcinoma
- Everolimus
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-12-16
Dec 16, 2021N
Completed
- Brain Tumor
- +2 more
- everolimus
- sorafenib
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-01-07
Jan 7, 2022Y
Terminated
- Breast Cancer
- Everolimus
- New Haven, ConnecticutYale University
2022-01-12
Jan 12, 2022B
Enrolling by invitation
- Progeria
- Everolimus and lonafarnib
- Boston, MassachusettsBoston Children's Hospital
2021-06-11
Jun 11, 2021Y
Recruiting
- Renal Cell Carcinoma
- Lenvatinib
- +2 more
- Iowa City, IowaUniversity of Iowa Hospitals and Clinics
2021-12-13
Dec 13, 2021U
Terminated
- Low Grade Glioma
- +3 more
- Everolimus
- Temozolomide
- San Francisco, CaliforniaUniversity of California, San Francisco
2021-11-03
Nov 3, 2021F
Not yet recruiting
- Renal Cell Carcinoma
- Anlotinib hydrochloride
- everolimus
- Shanghai, China270 Dongan Road, Fudan University Shanghai Cancer Center
2021-11-05
Nov 5, 2021T
Active, not recruiting
- Differentiated Thyroid Cancer
- Everolimus
- Sorafenib
- Philadelphia, PennsylvaniaHospital of the University of Pennsylvania
2021-10-18
Oct 18, 2021E
Completed
- Solid Organ Malignancies
- +2 more
- Lenalidomide
- Everolimus
- Atlanta, Georgia
- +1 more
2021-11-19
Nov 19, 2021U
Recruiting
- Classical Hodgkin Lymphoma
- Itacitinib
- Everolimus
- Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
2021-07-23
Jul 23, 2021S
Completed
- Breast Cancer
- Everolimus
- +4 more
- Guangzhou, Guangdong, ChinaSun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
2021-09-22
Sep 22, 2021N
Completed
- Epilepsy
- +2 more
- Everolimus
- New York, New YorkNew York University Langone Medical Center
2021-08-31
Aug 31, 2021S
Active, not recruiting
- Glioblastoma Multiforme
- Glioma of Brain
- Ribociclib
- Everolimus
- Chandler, Arizona
- +2 more
2022-03-10
Mar 10, 2022U
Terminated
- Breast Neoplasms
- +2 more
- letrozole
- +2 more
- Baltimore, MarylandUniversity of Maryland Marlene & Stewart Greenebaum Cancer Cente
2022-02-09
Feb 9, 2022A
Active, not recruiting
- Breast Cancer
- Ovarian Cancer
- niraparib
- everolimus
- Sioux Falls, South DakotaAvera Cancer Institute
2021-08-24
Aug 24, 2021U
Terminated
- Glioma
- +2 more
- Dasatinib
- Everolimus
- Ann Arbor, MichiganUniversity of Michigan Cancer Center
2021-10-12
Oct 12, 2021H
Completed
- Kidney Transplant Infection
- Sirolimus
- +2 more
- São Paulo, Sao Paulo, BrazilHospital do Rim
2021-08-23
Aug 23, 2021U
Active, not recruiting
- Recurrent Childhood Ependymoma
- Everolimus
- Stanford, California
- +3 more
2022-01-31
Jan 31, 2022T
Suspended
- Thyroid Cancer
- Lenvatinib
- Everolimus
- Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
2021-10-07
Oct 7, 2021M
Completed
- Prostate Cancer
- apalutamide
- Everolimus
- New York, New YorkMemorial Sloan Kettering Cancer Center
2021-06-29
Jun 29, 2021M
Active, not recruiting
- Advanced Cancers
- Solid Tumors
- Pazopanib
- Everolimus
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2021-06-15
Jun 15, 2021H
Withdrawn
- Facial Angiofibromas
- Everolimus
- Placebo
- Bron, FranceHopital Femme Mère Enfant
2021-04-28
Apr 28, 2021